151751-Najiba-Chargi

193 Systemic therapy: skeletal muscle mass and chemoradiotherapy REFERENCES 1. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality pat - terns in Europe: Estimates for 40 coun- tries and 25 major cancers in 2018. Eur J Cancer . 2018;103:356-387. doi:10.1016/j. ejca.2018.07.005 2. Pressoir M, Desné S, Berchery D, et al. Prev - alence, risk factors and clinical implications of malnutrition in french comprehensive cancer centres. Br J Cancer . 2010;102(6):966- 971. doi:10.1038/sj.bjc.6605578 3. Elliott JA, Doyle SL, Murphy CF, et al. Sarco - penia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esopha- geal Cancer. Ann Surg . 2017;266(5):822-830. doi:10.1097/SLA.0000000000002398 4. Chargi N, Bril SI, Swartz JE, Wegner I, Wil - lems SW, de Bree R. Skeletal muscle mass is an imaging biomarker for decreased sur- vival in patients with oropharyngeal squa- mous cell carcinoma. Oral Oncol . 2020;101. doi:10.1016/j.oraloncology.2019.104519 5. Ansari E, Chargi N, van Gemert JTM, et al. Low skeletal muscle mass is a strong pre- dictive factor for surgical complications and a prognostic factor in oral cancer patients undergoing mandibular reconstruction with a free fibula flap. Oral Oncol . 2020;101. doi:10.1016/j.oraloncology.2019.104530 6. Sawyer M, RatainMJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs . 2001;19(2):171- 177. doi:10.1023/A:1010639201787 7. Astolfi L, Ghiselli S, Guaran V, et al. Cor - relation of adverse effects of cisplatin ad - ministration in patients affected by solid tumours: A retrospective evaluation. Oncol Rep . 2013;29(4):1285-1292. doi:10.3892/ or.2013.2279 8. Wendrich AW, Swartz JE, Bril SI, et al. Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. 2017. doi:10.1016/j.oraloncol - ogy.2017.05.012 9. Ali R, Baracos VE, Sawyer MB, et al. Lean body mass as an independent determi- nant of dose-limiting toxicity and neurop- athy in patients with colon cancer treat- ed with FOLFOX regimens. Cancer Med . 2016;5(4):607-616. doi:10.1002/cam4.621 10. Sjøblom B, Grønberg BH, Benth JŠ, et al. Lowmusclemass is associatedwith chemo- therapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer . 2015;90(1):85-91. doi:10.1016/j. lungcan.2015.07.001 11. Kurk S, Peeters P, Stellato R, et al. Skel - etal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle . 2019;10(4):803-813. doi:10.1002/jcsm.12436 12. Hopkins JJ, Sawyer MB. Expert Review of Clinical Pharmacology A review of body composition and pharmacokinetics in on- cology A review of body composition and pharmacokinetics in oncology. 2017. doi:1 0.1080/17512433.2017.1347503 13. Hilmi M, Jouinot A, Burns R, et al. Body com - position and sarcopenia: The next-genera- tion of personalized oncology and pharma- cology? Pharmacol Ther . 2019;196:135-159. doi:10.1016/j.pharmthera.2018.12.003 14. Mitsiopoulos N, Baumgartner RN, Heyms - field SB, et al. Cadaver Validation of Skeletal MuscleMeasurement byMagnetic Resonance Imaging and Computerized Tomography .; 1998. http://www.jap.org. 10